AstraZeneca, Bristol Myers are in talks about merger — report
AstraZeneca is in talks with Bristol Myers Squibb about a merger that would be one of the industry’s largest ever, according to a report Sunday by the Financial Times. A deal would combine the UK ...
AstraZeneca and Bristol Myers Squibb are in talks about a potential merger. According to the Financial Times, a deal would create one of the largest pharmaceutical companies in the world. The combined value of the two companies is around $400 billion.
AstraZeneca, valued at around $264 billion, and Bristol Myers Squibb, valued at around $133 billion, have been discussing a merger in recent months. If completed, the deal would be one of the largest in industry history.
The merger would further AstraZeneca's focus on the US market, according to Handelsblatt. AstraZeneca's CEO Pascal Soriot has been pursuing this strategy, including upgrading the company's listing in New York in June.
Brief written by urgent.news from Endpoints News, Handelsblatt — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
